Related Experiment Video
Updated: Jul 9, 2026
05:16
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very
Piotr Kubler1, Ewa A Jankowska, Jacek Majda
1Cardiology Department, Military Hospital, Wroclaw, Poland.
International Journal of Cardiology
|December 7, 2007
Summary
A significant decrease in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels during hospitalization indicates a better prognosis for acute heart failure patients. Monitoring NT-proBNP reduction is crucial for effective risk stratification.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Research
Background:
- Optimal risk stratification for acute heart failure survivors remains undefined.
- Investigating NT-proBNP decrease as a predictor of poor outcomes in acute heart failure.
Purpose of the Study:
- To determine if a lack of significant NT-proBNP decrease during hospitalization identifies high-risk acute heart failure patients.
- To establish NT-proBNP level monitoring as a tool for risk stratification.
Main Methods:
- 103 consecutive acute heart failure patients were studied.
- Primary endpoint: all-cause mortality at 1-year follow-up.
- NT-proBNP levels were measured on admission and after clinical stabilization.
Main Results:
- A decrease in NT-proBNP levels predicted a favorable outcome (p<0.001).
- A 65% NT-proBNP decrease was the optimal cut-off for predicting mortality (AUC=0.65).
- 1-year survival was 92% for NT-proBNP decrease >=65% vs. 66% for <65% (p=0.02).
Conclusions:
- The magnitude of NT-proBNP decrease aids in discriminating high-risk patients.
- Monitoring plasma NT-proBNP levels is vital for risk stratification in acute heart failure.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...